Table 3.

Discharge and post-discharge outcomes by time between discontinuation of anti-fibrotic medication and transplant (N = 297).

	Time between discontinuation of anti-fibrotic medication and transplant		p-value
Outcome	Shorter (n = 211)	Longer (n = 86)
Discharged home a	161 (76.3)	75 (87.2)	0.035
Alive 30 days after transplant	201 (95.7) b	82 (95.3)	0.89
Alive 90 days after transplant	196 (93.8) c	82 (95.3)	0.60
Alive 6 months after transplant	190 (90.9) c	80 (93.0)	0.55
Acute rejection during 6 months after transplant	87 (42.0) d	39 (45.3)	0.60
Bronchiolitis obliterans syndrome or restrictive allograft syndrome during 6 months after transplant	1 (0.5) e	0 (0)	0.52
Resumed anti-fibrotic medication	0 (0) d	0 (0)

Data are n (%). Shorter: discontinued anti-fibrotic medication ⩽ 5 medication half-lives before transplant; longer: discontinued anti-fibrotic medication > 5 medication half-lives before transplant.

^aPatient went home following discharge as opposed to being transferred to a skilled nursing, acute rehabilitation, or long-term acute care facility.

^bN = 210.

^cN = 209.

^dN = 207.

^eN = 204.